Skip to main content

Table 2 Disease-specific summary of significant different biomarkers in cerebrospinal fluid

From: Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

Protein

Controls

PD

MSA

CCL28

0.6 ± 0.2b

0.9 ± 0.2a

0.8 ± 0.2

IL-8

8.4 ± 1.3bc

7.6 ± 0.5a

7.5 ± 0.4a

FGF-19

4.7 ± 0.8c

4.2 ± 0.6

3.9 ± 0.7a

CD40

8.1 ± 0.5c

7.6 ± 0.4

7.5 ± 0.4a

PD-L1

4.1 ± 0.6c

3.7 ± 0.5

3.5 ± 0.4a

TGF-α

6.0 ± 0.6c

5.7 ± 0.4

5.5 ± 0.4a

SCF

5.2 ± 0.7c

4.8 ± 0.5

4.7 ± 0.3a

CSF-1

6.9 ± 0.5c

6.5 ± 0.4

6.3 ± 0.2a

uPA

6.0 ± 0.6c

7.0 ± 0.5

6.8 ± 0.4a

VEGF-A

9.6 ± 0.7c

9.1 ± 0.6

8.9 ± 0.4a

CCL23

3.1 ± 1.0bc

2.5 ± 0.5a

2.5 ± 0.3a

CX3CL1

3.2 ± 0.6bc

2.6 ± 0.5a

2.4 ± 0.3a

MCP-2

5.0 ± 0.9bc

4.2 ± 0.8a

4.2 ± 0.5a

CXCL1

6.0 ± 1.2bc

4.9 ± 0.5a

4.9 ± 0.6a

DNER

10.0 ± 0.2c

9.9 ± 0.2c

9.8 ± 0.1ab

β-NGF

1.8 ± 0.5c

1.5 ± 0.3c

1.3 ± 0.2ab

  1. Data are expressed as normalized protein expression (NPX) values (mean ± standard deviation). Data were analyzed using rank analysis of covariance followed by ANOVA with Games Howell as a post hoc test. Only statistically significant (p < 0.05) differences are noted. aversus controls; bversus Parkinson’s disease (PD); cversus multiple system atrophy (MSA)